ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dazodalibep

Also written as “VIB4920”, “Dazodalibep” and “Inebilzumab+VIB4920”.

Its studies are mostly in Sjogren's Syndrome · Arthritis, Rheumatoid, led by 2 companies.

Drug pageDazodalibep: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 23, 20239 company-led studies, 2 open or runningNext primary completion: Dec 11, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only82 open or runningphase 3since Oct 23, 2023May 3, 2016Dec 11, 2029phase 3 · NCT06747949
AstraZeneca10 open or runningphase 1since May 27, 2014May 27, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 27, 2014First study: phase 1 study in Healthy VolunteerFirst studyNCT02151110 · 59 enrolled · United Kingdom
  2. Jun 9, 2020Named dazodalibepINNProposed as its International Nonproprietary Name in WHO's List 123 · before, VIB4920

TargetBeta

CD40LG →read by rule
“CD40 ligand antagonist”ChEMBL 37, by rule

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
frexalimabSanofiphase 311
dapirolizumab pegolruleUCBphase 38
tegoprubartruleeledon-pharmaceuticalsphase 38
ravagalimabruleAbbViephase 24
OPT101ruleop-t-llcphase 24
TNX-1500ruleTonix Pharmaceuticalsphase 11

Studies

The one study AstraZeneca leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02151110Healthy Volunteer · United Kingdom1CompletedMay 9, 201659

How it is read

Names in the registry

  • “VIB4920”, 5 entries
  • “Dazodalibep”, 3 entries
  • “Inebilzumab+VIB4920”, 1 entry
  • “MEDI4920 3 mg”, 1 entry
  • “MEDI4920 10 mg”, 1 entry

Codes read as this program: VIB4920.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.